BiotechTube

Sugammadex + Neostigmine + Glycopyrrolate

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Surgical Procedures, Elective

Conditions

Surgical Procedures, Elective

Trial Timeline

Dec 2, 2011 → Nov 5, 2012

NCT ID
NCT01479764

About Sugammadex + Neostigmine + Glycopyrrolate

Sugammadex + Neostigmine + Glycopyrrolate is a phase 3 stage product being developed by Merck for Surgical Procedures, Elective. The current trial status is completed. This product is registered under clinical trial identifier NCT01479764. Target conditions include Surgical Procedures, Elective.

What happened to similar drugs?

7 of 20 similar drugs in Surgical Procedures, Elective were approved

Approved (7) Terminated (5) Active (10)
🔄Nivolumab + EverolimusOno PharmaceuticalPhase 3
✅Epoetin alfa + Standard of CareJohnson & JohnsonApproved
✅ErtapenemMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅Deep neuromuscular blockMerckApproved
✅RocuroniumMerckApproved
🔄Insulin infusion with a goalNovo NordiskPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02860507ApprovedCompleted
NCT01479764Phase 3Completed

Competing Products

20 competing products in Surgical Procedures, Elective

See all competitors
ProductCompanyStageHype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
CelecoxibAstellas PharmaPre-clinical
26
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
Epoetin alfa + Standard of CareJohnson & JohnsonApproved
35
HR021618 + HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
31
SHR0410 Injection + Placebo for SHR0410 InjectionJiangsu Hengrui MedicinePhase 2
27
ErtapenemMerckApproved
43
Sugammadex + RocuroniumMerckApproved
43
Deep neuromuscular blockMerckApproved
43
RocuroniumMerckApproved
43
ErtapenemMerckPhase 2/3
38
Ecallantide + PlaceboMerckPhase 2
27
Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)Novo NordiskPhase 1
36
Insulin infusion with a goalNovo NordiskPhase 3
40
parecoxib/valdecoxibPfizerApproved
35
Tranexamic acid + Standard of CarePfizerApproved
43
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + PlaceboPfizerPhase 3
40
valdecoxib + valdecoxib/placebo + placeboPfizerPhase 3
40
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
27